Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells
Yosuke Harazono1, Dhong Hyo Kho1, Vitaly Balan2
1Departments of Oncology and Pathology, School of Medicine, Wayne State University, and Karmanos Cancer Institute, Detroit, MI.
Abstract:
Cancer cells survive escaping normal apoptosis and the blocks in apoptosis that keep cancer cells alive are promising candidates for targeted therapy. Galectin-3 (Gal-3) is, a member of the lectin family, which is involved in cell growth, adhesion, proliferation and apoptosis. It remains elusive to understand the role of Gal-3 on apoptosis in thyroid carcinoma cells. Here, we report that Gal-3 heterodimerizes Bax, mediated by the carbohydrate recognition domain (CRD) of Gal-3, leading to anti-apoptotic characteristic. Gal-3/Bax interaction was suppressed by an antagonist of Gal-3, in which in turn cells became sensitive to apoptosis. The data presented here highlight that Gal-3 is involved in the anti-apoptosis of thyroid carcinoma cells. Thus, it suggests that targeting Gal-3 may lead to an improved therapeutic modality for thyroid cancer.
Insights
Targeting cancer cell survival, this study reveals Galectin-3 (Gal-3) promotes thyroid cancer cell anti-apoptosis by interacting with Bax. Inhibiting Gal-3 restores apoptosis, suggesting it as a therapeutic target for thyroid cancer.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Cancer cells evade apoptosis, a key mechanism for survival and therapeutic resistance.
- Galectin-3 (Gal-3), a lectin, influences cell processes including apoptosis, but its role in thyroid carcinoma is unclear.
Purpose of the Study:
- To elucidate the role of Galectin-3 (Gal-3) in regulating apoptosis within thyroid carcinoma cells.
- To investigate the molecular mechanism by which Gal-3 affects apoptosis in thyroid cancer.
Main Methods:
- Investigated Gal-3 interaction with Bax using biochemical assays.
- Utilized a Gal-3 antagonist to assess its impact on apoptosis sensitivity.
- Examined the role of Gal-3's carbohydrate recognition domain (CRD) in mediating interactions.
Main Results:
- Galectin-3 (Gal-3) forms heterodimers with Bax, mediated by its CRD, conferring anti-apoptotic properties.
- Suppression of Gal-3/Bax interaction using a Gal-3 antagonist sensitized thyroid carcinoma cells to apoptosis.
- Confirmed Gal-3's involvement in promoting the survival of thyroid carcinoma cells.
Conclusions:
- Galectin-3 (Gal-3) plays a significant role in the anti-apoptotic mechanisms of thyroid carcinoma.
- Targeting Galectin-3 presents a potential therapeutic strategy for enhancing apoptosis and treating thyroid cancer.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
Apoptosis
The Intrinsic Apoptotic Pathway
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The Extrinsic Apoptotic Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
